Refractory neuroendocrine tumor - Response to liposomal doxorubicin and capecitabine

Nature Reviews Clinical Oncology

Volumn 6, Issue 11, 2009, Pages 670-674

  Masi, Gianluca ^a   Fornaro, Lorenzo ^a   Cupini, Samanta ^b   Loupakis, Fotios ^a   Vasile, Enrico ^a   Baldi, Giacomo G ^a   Stasi, Irene ^a   Salvatore, Lisa ^a   Falcone, Alfredo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Livorno Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; OCTREOTIDE;

ADULT; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOID; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TRACT EXAMINATION; HEPATOMEGALY; HUMAN; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER TUMOR; LUNG HILUS; LUNG LESION; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; THORAX RADIOGRAPHY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NEUROENDOCRINE; CISPLATIN; DEOXYCYTIDINE; DOXORUBICIN; ETOPOSIDE; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; OCTREOTIDE; TREATMENT OUTCOME;

EID: 70350772373     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.148     Document Type: Review

References (14)

1. NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network: Your best resource in the fight against cancer [online], http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (2009).
2. De Vita, V. T Jr et al. in DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 8th edn Ch. 44 (Lippincott, Williams & Wilkins, Philadelphia, 2008).
3. Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92 205-216 (2000).
4. Granberg, D. et al. Octreoscan in patients with bronchial carcinoid tumours. Clin. Endocrinol. (Oxf.) 59, 793-799 (2003).
5. Musi, M. et al. Bronchial carcinoid tumours: A study on clinicopathological features and role of octreotide scintigraphy. Lung Cancer 22, 97-102 (1998).
6. Oberg, K. Carcinoid tumors: Molecular genetics, tumor biology, and update of diagnosis and treatment. Curr. Opin. Oncol. 14, 38-45 (2002).
7. Asamura, H. et al. Neuroendocrine neoplasms of the lung: A prognostic spectrum. J. Clin. Oncol. 24, 70-76 (2006).
8. Anderson, A. S. et al. Cardiovascular complications of malignant carcinoid disease. Am. Heart J. 134, 693-702 (1997).
9. Kwekkeboom, D. J. et al. Somatostatin analogue scintigraphy in carcinoid tumours. Eur. J. Nucl. Med. 20, 283-292 (1993).
10. Tzannou, I. A. et al. The use of radiolabeled somatostatin analog scintigraphy in the staging of small cell lung cancer patients. Am. J. Clin. Oncol. 30, 503-506 (2007).
11. Gustafsson, B. I. et al. Bronchopulmonary neuroendocrine tumors. Cancer 113, 5-21 (2008).
12. Kosmidis, P. A. Treatment of carcinoid of the lung. Curr. Opin. Oncol. 16, 146-149 (2004).
13. Bajetta, E. et al. Update on the treatment of neuroendocrine tumors. Expert Rev. Anticancer Ther. 3, 631-642 (2003).
14. 111In-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J. Nucl. Med. 44, 1-6 (2003).